Anti-VEGF Market to grow at a CAGR of 4.3% during 2025 to 2035; Driven by Rising Prevalence of Retinal Disorders and Increasing Demand for Anti-VEGF Therapies

Anti VEGF Market Highlights

The Anti-VEGF Market Size was valued at USD 25.98 Billion in 2024. The market is projected to grow from USD 27.1 Billion in 2025 to USD 41.3 Billion by 2035, registering a CAGR of 4.3% during the forecast 2025–2035.

The Anti-VEGF (Vascular Endothelial Growth Factor) market is expanding due to several factors. Firstly, the rising prevalence of diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal vascular disorders fuels demand for anti-VEGF therapies. Additionally, advancements in biotechnology have led to the development of more effective and targeted anti-VEGF drugs. Furthermore, increasing adoption of these therapies in emerging economies, coupled with aging populations globally, contributes to the overall growth of the Anti-VEGF market.

MRFR recognizes the following companies as the key players in the global Anti-VEGF market— Regeneron Pharmaceuticals, Novartis AG, Roche, Bayer AG, Allergan plc, Pfizer Inc., Bausch Health Companies Inc., AbbVie Inc., Santen Pharmaceutical Co., Ltd., Alcon Inc., and Others.

Segment Analysis

The global Anti-VEGF market has been segmented based on Product and Disease.

On the basis of Product, the market is segmented into Eylea, Lucentis, And Beovu. The Eylea segment captured the largest market share in the Anti-VEGF Market in 2025 due to its proven efficacy and safety profile in treating retinal diseases such as age-related macular degeneration and diabetic retinopathy. Its longer dosing intervals compared to other anti-VEGF agents provide convenience for patients and healthcare providers. Moreover, extensive clinical evidence and strong marketing strategies further solidified Eylea's position as a leading product in the market.

Based on Disease, the global Anti-VEGF market has been segmented into Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, And Age-Related Macular Degeneration. The Macular Edema segment secured the largest market share in the Anti-VEGF Market in 2025 due to its high prevalence and significant impact on vision loss. As a common complication of retinal diseases such as diabetic retinopathy and age-related macular degeneration, the demand for effective treatments, including anti-VEGF therapies, is substantial. Additionally, advancements in diagnosis and increased awareness among patients and healthcare professionals further drove market growth.

Regional Analysis

The global Anti-VEGF market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Anti-VEGF market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Anti-VEGF market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Anti-VEGF market comprises the Middle East, Africa, and Latin America.

North America dominated the Anti-VEGF Market in 2025 primarily due to several factors. These include a high prevalence of retinal diseases, advanced healthcare infrastructure facilitating widespread access to treatment, and robust reimbursement policies supporting expensive therapies. Additionally, extensive research and development activities, coupled with early adoption of innovative treatments, contributed to North America's leading position in the Anti-VEGF Market.

Europe secured the second-largest market share in the Anti-VEGF Market in 2025 due to factors such as a significant patient population suffering from retinal diseases, advanced healthcare systems, and well-established regulatory frameworks facilitating the approval and adoption of anti-VEGF therapies. Moreover, increasing awareness among healthcare professionals and patients about the benefits of these treatments further fueled market growth in Europe.

Asia Pacific is experiencing the highest compound annual growth rate (CAGR) in the Anti-VEGF Market due to several factors. These include a rapidly increasing geriatric population, rising prevalence of retinal diseases, improving healthcare infrastructure, and expanding access to advanced therapies. Additionally, increasing healthcare expenditure, growing awareness about eye health, and rising investments in research and development contribute to the significant growth potential in the Asia Pacific region.

Furthermore, the rest of the world's Anti-VEGF market is divided into the Middle East, Africa, and Latin America. The rest of the world is experiencing growth in the Anti-VEGF market due to factors such as improving healthcare infrastructure, rising awareness about retinal diseases, and increasing availability of advanced treatment options. Additionally, expanding healthcare expenditure and growing partnerships with global pharmaceutical companies contribute to market expansion in these regions.

Key Findings of the Study

• The Market reached USD 25.98 billion in 2024 and is projected to reach USD 41.3 billion by 2035.


• Global AMD prevalence is projected to rise from 196 million in 2020 to 288 million by 2040, expanding treatment demand.


• Amgen’s PAVBLU generated USD 99 million in Q1 2025, strengthening biosimilar competition within the market.